Bristol-Myers Sues Teva To Block Generic Baraclude

Law360, New York (September 24, 2010, 12:19 PM EDT) -- Bristol-Myers Squibb Co. has slapped Teva Pharmaceutical Industries Ltd. with a lawsuit, accusing it of infringing a patent covering the hepatitis B drug Baraclude.

New Jersey-based Bristol-Myers said in the suit filed Wednesday in the U.S. District Court for the District of Delaware that Teva and its affiliate must be stopped from making and selling entecavir, a generic of Baraclude.

By filing an abbreviated new drug application, Teva is infringing on U.S. Patent No. 5,206,244, issued in 1993 and entitled “Hydroxymethyl (Methylenecyclopentyl) Purines and Pyrimidines,” the...
To view the full article, register now.